ERBB2 and breast carcinoma: Among the three treatment cohorts, the HER2-targeted cohort had the highest preperiod treatment rate with breast cancer-related surgery (26.0%, P < 0.001), radiation therapy (17.9%, P < 0.001), and chemotherapy (44.5%, P < 0.001).